Xen reduces both IOP and medication use in refractory glaucoma

CORONADO, Calif. — In a group of refractory glaucoma patients, the ab interno placement of Allergan’s Xen45 gel stent reduced both IOP and medication use at 12 months, Davinder S. Grover, MD, MPH, and colleagues reported in a poster presented at the American Glaucoma Society meeting.Of 65 patients implanted with the gel stent, 76.3% achieved a 20% or greater reduction in IOP from baseline, and 69.2% of patients needed fewer medications. At baseline, 84.6% of patients were using more than three hypotensive medications; the mean number of medications decreased from (Read more...)

Full Story →